Tag: Novo Nordisk
-

Is investing in Novo Nordisk a mistake? The “Ozempic Patent Cliff” in India
Discover why the Ozempic patent expiring in India on March 20, 2026, is a major shift for investors. Learn which industries will win and why Novo Nordisk (NVO) faces a “generic tsunami.”
-

Ozempic, India, and the Great American Drug Pricing Scam
in OpinionWhy does Ozempic cost $104/month in India but nearly $1,000 in the U.S.? The answer isn’t R&D — it’s a broken, exploitative drug pricing system.
